Literature DB >> 16482568

Renin-angiotensin system is an important factor in hormone refractory prostate cancer.

Hiroji Uemura1, Hisashi Hasumi, Hitoshi Ishiguro, Jun-ichi Teranishi, Yasuhide Miyoshi, Yoshinobu Kubota.   

Abstract

BACKGROUND: The aim of this study was to perform a comprehensive evaluation of the renin-angiotensin system (RAS) in prostate cancer.
METHODS: We investigated the expression of RAS components in prostate cancer cells treated with hormonal agents. Real-time PCR data showed the expression of the AT1 receptor, angiotensin I converting enzyme (ACE), and angiotensin I/II (Ang-I/II) precursor in all 87 prostate tissue samples.
RESULTS: Expression of these genes in hormone refractory prostate cancer (HRPC) was significantly higher than that in normal prostate tissue and untreated prostate cancer tissue. Western blot showed that protein expression of the AT1 receptor and Ang-I/II was enhanced in LNCaP cells cultivated in steroid-free medium. When LNCaP cells were stimulated with dihydrotestosterone (DHT), estradiol (E2), dexamethasone (DEX), or anti-androgen drugs, protein expression of the AT1 receptor and Ang-I/II was augmented.
CONCLUSIONS: The present data suggest that prostatic RAS is overexpressed in HRPC tissue, and expression of its components is influenced by several kinds of hormonal stimulation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16482568     DOI: 10.1002/pros.20407

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  16 in total

1.  Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: relative changes of parathyroid hormone-related protein and its parathyroid hormone 1 receptor, osteoprotegerin and receptor activator of nuclear factor-kB ligand.

Authors:  Francisco C Pérez-Martínez; Verónica Alonso; José L Sarasa; Syon-Ghyun Nam-Cha; Remigio Vela-Navarrete; Félix Manzarbeitia; Francisco J Calahorra; Pedro Esbrit
Journal:  J Clin Pathol       Date:  2006-06-14       Impact factor: 3.411

2.  The renin angiotensin system regulates Kupffer cells in colorectal liver metastases.

Authors:  Shu Wen Wen; Eleanor I Ager; Jaclyn Neo; Christopher Christophi
Journal:  Cancer Biol Ther       Date:  2013-06-17       Impact factor: 4.742

3.  Enhanced mesenteric arterial responsiveness to angiotensin II is androgen receptor-dependent in prenatally protein-restricted adult female rat offspring.

Authors:  Kunju Sathishkumar; Meena P Balakrishnan; Chandrasekhar Yallampalli
Journal:  Biol Reprod       Date:  2014-12-30       Impact factor: 4.285

4.  Angiotensin-converting enzyme insertion/deletion polymorphism and the risk of prostate cancer in the Han population of China.

Authors:  Xiao Wang; Shuai Wang; Yi-wei Lin; Jian Wu; Hong Chen; Ye-qing Mao; Xiang-yi Zheng; Cheng Zhou; Li-ping Xie
Journal:  Med Oncol       Date:  2011-08-28       Impact factor: 3.064

Review 5.  The renin-angiotensin system and cancer: old dog, new tricks.

Authors:  Amee J George; Walter G Thomas; Ross D Hannan
Journal:  Nat Rev Cancer       Date:  2010-10-22       Impact factor: 60.716

6.  Androgen increases AT1a receptor expression in abdominal aortas to promote angiotensin II-induced AAAs in apolipoprotein E-deficient mice.

Authors:  Tracy Henriques; Xuan Zhang; Frederique B Yiannikouris; Alan Daugherty; Lisa A Cassis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-05-01       Impact factor: 8.311

7.  Alterations in Gene Expression of Components of the Renin-Angiotensin System and Its Related Enzymes in Lung Cancer.

Authors:  Benjamin Goldstein; Malav Trivedi; Robert C Speth
Journal:  Lung Cancer Int       Date:  2017-07-16

Review 8.  The ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Pleiotropic Roles in Cancer.

Authors:  Juanjuan Xu; Jinshuo Fan; Feng Wu; Qi Huang; Mengfei Guo; Zhilei Lv; Jieli Han; Limin Duan; Guorong Hu; Lian Chen; Tingting Liao; Wanli Ma; Xiaonan Tao; Yang Jin
Journal:  Front Physiol       Date:  2017-05-08       Impact factor: 4.566

9.  Chemopreventive effects of angiotensin II receptor type 2 agonist on prostate carcinogenesis by the down-regulation of the androgen receptor.

Authors:  Yusuke Ito; Aya Naiki-Ito; Hiroyuki Kato; Shugo Suzuki; Toshiya Kuno; Yukari Ishiguro; Satoru Takahashi; Hiroji Uemura
Journal:  Oncotarget       Date:  2018-02-14

10.  Effect of an angiotensin II type 1 receptor blocker on caveolin-1 expression in prostate cancer cells.

Authors:  Agnieszka Wanda Piastowska-Ciesielska; Marcin Kozłowski; Waldemar Wagner; Kamila Domińska; Tomasz Ochędalski
Journal:  Arch Med Sci       Date:  2012-10-08       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.